Concord Biotech Ltd (NSE: CONCORDBIO, BSE: 543960) is a Ahmedabad, Gujarat-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹14,008 Cr, it ranks #489 by market cap among the 6,137 Indian listed companies on FinBizNet, and #8 of 11 in Pharmaceutical CDMO and CRO Services. At ₹1,229.30 (as of 25 Oct 2026), the share price is 23.9% below its 52-week high of ₹1,615.00 and 24.5% above its 52-week low of ₹987.00. The share price is down 19.5% over one year and down 1.5% over three months.
| Current Price | ₹1,229.30 |
|---|---|
| Market Cap | ₹14,008 Cr |
| NSE Symbol | CONCORDBIO |
| BSE Code | 543960 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 51.7 |
| Return on Equity | 13.54% |
| Return on Assets | 8.91% |
| 52-Week Range | ₹987.00 – ₹1,615.00 |
| 1-Year Price Change | -19.5% |
| 3-Month Price Change | -1.5% |
| Beta (1Y) | 0.09 |
| Dividend Yield | 0.59% |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.concordbiotech.com |
| Revenue | ₹257 Cr |
|---|---|
| Net Profit | ₹56 Cr |
| Net Margin | 21.9% |
| EPS (Basic) | ₹5.52 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomyci
1. Manufacturing and trading in pharmaceutical products-This segment engages in researching, developing, manufacturing, marketing, and selling pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Manufacturing and trading in pharmaceutical products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹2,42,758 Cr | 93.8 | 16.19% | ₹3,080 Cr | +35.6% |
| Anthem Biosciences Limited | ₹46,303 Cr | 77.5 | 19.45% | ₹418 Cr | +5.3% |
| Sai Life Sciences Limited | ₹29,513 Cr | 85 | 15.13% | ₹554 Cr | +58.5% |
| Cohance Lifesciences Ltd | ₹17,754 Cr | 97.9 | 5.11% | ₹422 Cr | -49.9% |
| Onesource Specialty Pharma Limited | ₹16,144 Cr | -213 | -1.26% | ₹449 Cr | -27.8% |
| Syngene International Ltd. | ₹15,371 Cr | 50.6 | 6.62% | ₹736 Cr | -42.7% |
| Jubilant Pharmova Ltd | ₹14,958 Cr | 37.3 | 5.96% | ₹2,229 Cr | -12.8% |
| Concord Biotech Ltd | ₹14,008 Cr | 51.7 | 13.54% | ₹257 Cr | -19.5% |
| Blue Jet Healthcare Ltd | ₹9,855 Cr | 35.5 | 19.88% | ₹293 Cr | -29.2% |
Listed by market capitalisation. Ratios are shown for context only.
Concord Biotech Ltd is trading at ₹1,229.30, with a market capitalisation of ₹14,008 Cr.
Concord Biotech Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Concord Biotech Ltd has a P/E of 51.7 and a return on equity of 13.54%.
Concord Biotech Ltd is listed on the NSE under the symbol CONCORDBIO and on the BSE under the scrip code 543960.
Concord Biotech Ltd's share price is down 19.5% over one year and down 1.5% over three months. Its 52-week range is ₹987.00 to ₹1,615.00.
In Q1 FY27, Concord Biotech Ltd reported revenue of ₹257 Cr and net profit of ₹56 Cr, with basic EPS of ₹5.52 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.